BR112017023484A2 - compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico - Google Patents

compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico

Info

Publication number
BR112017023484A2
BR112017023484A2 BR112017023484A BR112017023484A BR112017023484A2 BR 112017023484 A2 BR112017023484 A2 BR 112017023484A2 BR 112017023484 A BR112017023484 A BR 112017023484A BR 112017023484 A BR112017023484 A BR 112017023484A BR 112017023484 A2 BR112017023484 A2 BR 112017023484A2
Authority
BR
Brazil
Prior art keywords
compounds
agonist activity
beta2 adrenergic
adrenergic receptor
receptor antagonist
Prior art date
Application number
BR112017023484A
Other languages
English (en)
Inventor
Rizzi Andrea
Knight Chris
Rancati Fabio
Linney Ian
Carzaniga Laura
Barnes Michael
Schmidt Wolfgang
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of BR112017023484A2 publication Critical patent/BR112017023484A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Abstract

a presente invenção refere-se aos compostos que agem tanto como antagonistas de receptor muscarínico quanto agonistas de receptor beta2 adrenérgico, aos processos para sua preparação, às composições compreendendo-os, aos usos terapêuticos e combinações com outros ingredientes ativos farmacêuticos.
BR112017023484A 2015-06-01 2016-05-31 compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico BR112017023484A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170033 2015-06-01
PCT/EP2016/062226 WO2016193241A1 (en) 2015-06-01 2016-05-31 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number Publication Date
BR112017023484A2 true BR112017023484A2 (pt) 2018-07-24

Family

ID=53385478

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023484A BR112017023484A2 (pt) 2015-06-01 2016-05-31 compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico

Country Status (10)

Country Link
US (1) US9662323B2 (pt)
EP (1) EP3303333B1 (pt)
KR (1) KR20180011121A (pt)
CN (1) CN107690432B (pt)
AR (1) AR104828A1 (pt)
BR (1) BR112017023484A2 (pt)
CA (1) CA2987471A1 (pt)
MX (1) MX2017015047A (pt)
RU (1) RU2709777C2 (pt)
WO (1) WO2016193241A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017093208A1 (en) * 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN110343068B (zh) * 2018-04-04 2022-02-11 沈阳药科大学 2-氨基-2-喹啉基乙醇类β2-受体激动剂及其制备方法和应用
FI20225388A1 (en) 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534343A (en) * 1984-01-27 1985-08-13 Trutek Research, Inc. Metered dose inhaler
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1685118B1 (en) 2003-11-21 2009-07-08 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
PL3210981T3 (pl) 2009-04-23 2019-06-28 Theravance Respiratory Company, Llc Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
PT2718280E (pt) 2011-06-10 2015-11-25 Chiesi Farma Spa Compostos possuindo uma atividade antagonista de um recetor muscarínico e agonista de um recetor beta2 adrenérgico
BR112013030302B1 (pt) * 2011-06-10 2021-08-24 Chiesi Farmaceutici S.P.A. Composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
RS60864B1 (sr) 2012-12-06 2020-11-30 Chiesi Farm Spa Jedinjenja koja imaju aktivnost antagonista muskarinskog receptora i agonista beta2 adrenergičkog receptora
ES2663878T3 (es) * 2012-12-06 2018-04-17 Chiesi Farmaceutici S.P.A. Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta-2 adrenérgico

Also Published As

Publication number Publication date
EP3303333B1 (en) 2019-11-20
RU2017141405A (ru) 2019-07-16
US9662323B2 (en) 2017-05-30
EP3303333A1 (en) 2018-04-11
CN107690432B (zh) 2019-12-24
CN107690432A (zh) 2018-02-13
RU2709777C2 (ru) 2019-12-20
WO2016193241A1 (en) 2016-12-08
CA2987471A1 (en) 2016-12-08
RU2017141405A3 (pt) 2019-07-30
KR20180011121A (ko) 2018-01-31
MX2017015047A (es) 2018-04-11
US20160346271A1 (en) 2016-12-01
AR104828A1 (es) 2017-08-16

Similar Documents

Publication Publication Date Title
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
BR112015012730A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
PH12017501424A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CL2016001895A1 (es) Compuestos
CL2015002402A1 (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenergico asi como actividad antagonista del receptor muscarínico m3.
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
NI201500080A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3.
CR20150322A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3
MD3628331T2 (ro) Procedeu de preparare unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CO2018005139A2 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
UY36329A (es) NUEVOS DERIVADOS BICÍCLICOS QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
BR112017023484A2 (pt) compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
CL2015003761A1 (es) Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
BR112013025682A2 (pt) Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo
BR112018075817A2 (pt) composto de fórmula (i), medicamento e composição farmacêutica
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ECSP15026152A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos m3
UA109581C2 (uk) Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2
BR112015015491A2 (pt) compostos (tieno[2,3-b][1,5] benzoxazepin-4-il) piperazin-1-ila com atividade dual como agonistas inversos h1/antagonistas 5-ht2a

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2673 DE 29-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.